Given results of the drug’s efficacy as a single agent in the RR setting and tolerability in combination with cyclophosphamide, doxorubicin, and prednisone (A+CHP) in a phase I study, the ECHELON-2 study was performed, leading to the registration of brentuximab vedotin as part of primary therapy in CD30-positive PTCL. The gene discussed is TNFRSF8; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.